Table 3.
Comparing topical Betamethasone and Olivederma on quality of life (DLQI scores) of patients with atopic dermatitis randomly allocated in interventions
| Indices | Phase | Betamethasone | Olivederma | p-value* |
|---|---|---|---|---|
| DLQI score | Baseline | 22 ± 3.2 | 18.3 ± 2.8 | < 0.001 |
| 6th week | 17.1 ± 5.4 | 7.2 ± 1.4 | ||
| p-value# | < 0.001 | < 0.001 | ||
| DLQI change | Excellent improve | 0 (0%) | 6 (31.6%) | < 0.001 |
| Mild improve | 7 (41.2%) | 13 (68.4%) | ||
| No changes | 9 (52.9%) | 0 (0%) | ||
| Exacerbated | 1 (5.9%) | 0 (0%) |
#Within-group (time effect) significance.
*Between-group (intervention * time effect) significance.